{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:37:02Z","timestamp":1790235422276,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>The use of elexacaftor\/tezacaftor\/ivacaftor (ETI) has been associated with increased fertility in women with cystic fibrosis (CF) and is increasingly used during pregnancy to support both maternal and fetal health. However, little is known about the pharmacokinetics (PK) of ETI during pregnancy, which is crucial for optimizing its efficacy and safety. This study aimed to predict the PK of ETI during pregnancy and to determine the maternal dose required to achieve therapeutic concentrations in both the maternal and fetus. The pregnancy physiological\u2010based pharmacokinetic (PBPK) model within the Simcyp Simulator was used to predict the maternal and feto\u2010placental exposure of ETI. Placental kinetics were parameterized using permeability parameters determined from the physicochemical properties of these compounds. The model closely predicted the observed data, with the observed ETI maternal plasma concentrations, cord concentrations, and infant plasma concentrations mostly falling within the range of predicted 5th to 95th percentiles. Steady\u2010state simulations up to gestational week 40 predicted a continuous decline in ETI concentrations, with the AUC declining to 32.4\u201337.5% of baseline levels by week 40. However, the 5th percentile of trough concentrations for ETI consistently remained above the efficacy thresholds, both in mother and fetus. Therefore, it appears reasonable to maintain standard dosing regimen during pregnancy, complemented by careful monitoring. A clinical trial, such as the ongoing Maternal and Fetal Outcomes in the Era of Modulators (MAYFLOWERS) study, is required to further confirm the efficacy and safety of ETI in this population.<\/jats:p>","DOI":"10.1002\/cpt.3705","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:49:29Z","timestamp":1746438569000},"page":"622-631","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Predicting Maternal and Fetal Exposures of Elexacaftor\u2013Tezacaftor\u2013Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models"],"prefix":"10.1002","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6696-3948","authenticated-orcid":false,"given":"Eunjin","family":"Hong","sequence":"first","affiliation":[{"name":"College of Pharmacy CHA University  Seongnam\u2010si South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1854-1214","authenticated-orcid":false,"given":"Mary F.","family":"Hebert","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy University of Washington  Seattle Washington USA"},{"name":"Departments of Obstetrics and Gynecology University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5582-2835","authenticated-orcid":false,"given":"Emily","family":"Fay","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynecology University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0735-4947","authenticated-orcid":false,"given":"Grant","family":"Turner","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine University of California Los Angeles  Santa Monica California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Eshaghian","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine University of California Los Angeles  Santa Monica California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-8044","authenticated-orcid":false,"given":"Aaron","family":"Trimble","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, School of Medicine Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-2119","authenticated-orcid":false,"given":"Peter S.","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Keck School of Medicine University of Southern California  Los Angeles California USA"},{"name":"USC Anton Yelchin CF Clinic  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0220-7131","authenticated-orcid":false,"given":"Adupa P.","family":"Rao","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, Keck School of Medicine University of Southern California  Los Angeles California USA"},{"name":"USC Anton Yelchin CF Clinic  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-3310","authenticated-orcid":false,"given":"Paul M.","family":"Beringer","sequence":"additional","affiliation":[{"name":"USC Anton Yelchin CF Clinic  Los Angeles California USA"},{"name":"Department of Clinical Pharmacy, Mann School of Pharmacy and Pharmaceutical Sciences University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13329"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050418"},{"key":"e_1_2_10_5_1","first-page":"47","article-title":"Pregnancy in people with cystic fibrosis treated with highly effective modulator therapy","volume":"145","author":"Goralski J.","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"e_1_2_10_6_1","article-title":"Comparison of two pregnancies with and without elexacaftor\u2013tezacaftor\u2013ivacaftor in a woman with cystic fibrosis","volume":"83","author":"Chamagne M.","year":"2023","journal-title":"Respir. Med. Res."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(22)00780-9"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.02.018"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.03.006"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.12.004"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000530261"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.04.005"},{"key":"e_1_2_10_13_1","article-title":"Experience to date with CFTR modulators during pregnancy and breastfeeding in the British Columbia cystic fibrosis clinic","volume":"40","author":"Goodwin J.","year":"2022","journal-title":"Respir. Med. Case. Rep."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2022.101776"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597440-000000000-00000"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-020-09711-2"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-020-09698-w"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.05.009"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2786"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.073957"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00836-3"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0685-y"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00973-0"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0618-1"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000711"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920007782109733"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-3782(84)90074-4"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2220960"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.075192"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123518"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060458"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26093"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-020-00124-7"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.05.018"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13324"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.01.011"},{"key":"e_1_2_10_37_1","volume-title":"Kalydeco [package insert]","year":"2020"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.577263"},{"key":"e_1_2_10_39_1","unstructured":"US Food and Drug Administration.Center for drug evaluation and research. Multi\u2010discipline review elexacaftor\/tezacaftor\/ivacaftor<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf> (2019)."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001289"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/1061186X.2012.716847"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-2028-8"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws427"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:57:50Z","timestamp":1755237470000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cpt.3705"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3705","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"2025-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}